Form 4: Arcellx Director Jill Carroll Reports Stock Option Grant

Director Jill Carroll reported the acquisition of stock options in Arcellx, Inc. on May 28, 2024.

Summary

• Jill Carroll, a director of Arcellx, Inc., reported a transaction involving derivative securities.
• On May 28, 2024, Carroll acquired stock options (right to buy) for 8,011 shares of Arcellx common stock at an exercise price of $51.30.
• The options vest on the earlier of May 28, 2025, or the next annual meeting of stockholders, contingent upon Carroll's continued service as a Service Provider.
• Following the transaction, Carroll directly owns 8,011 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral in sentiment. It indicates alignment of director interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, incentivizing value creation.

Key Dates